• CA-074 Me: Cathepsin B Inhibitor Guide

  2026-08-24

  A scenario-based guide to using CA-074 Me (Cathepsin B inhibitor), SKU A8239, in viability, apoptosis, lysosomal, and necroptosis workflows. It connects biochemical potency, solvent handling, controls, and vendor-selection criteria with current evidence on lysosomal membrane permeabilization.

• Trypsin as a Translational Protease Strategy

  2026-08-24

  A thought-leadership guide to using Trypsin as both a mechanistic perturbation and a controlled research reagent, linking proteolytic design to osteoarthritis biology, cell-state studies, viral membrane fusion, wound healing research, and translational assay strategy.

• Adefovir (GS-0393): From Mechanism to Translation

  2026-08-23

  A translational perspective on Adefovir as a selective HBV DNA polymerase inhibitor and OAT1 probe, connecting molecular mechanism, assay design, exposure alignment, resistance biology, and renal safety strategy for hepatitis B virus research.

• S-Adenosylmethionine: From Methyl Donor to CNS Strategy

  2026-08-22

  S-Adenosylmethionine, also called Ademetionine or SAMe, is more than a generic methyl donor. Its position at the intersection of epigenetic regulation, neurotransmitter metabolism, transsulfuration, and cellular growth signaling makes it a strategic variable in translational research. This article connects mechanism, assay design, product selection, and neurological relevance to help researchers use SAM with greater experimental precision.

• nor-Binaltorphimine dihydrochloride: KOR Assays

  2026-08-22

  Build more discriminating opioid receptor signaling research workflows with nor-Binaltorphimine dihydrochloride, a selective κ-opioid receptor antagonist for separating KOR-dependent effects from MOR-driven responses. This guide translates a brain-to-spinal pain circuit study into practical assay design, stock-preparation choices, controls, and troubleshooting steps.

• LPS Protection of Macrophages Against Antitumor Drugs

  2026-08-21

  Qiao and colleagues show that lipopolysaccharide protects RAW264.7 macrophages from antitumor drug injury through a redox- and transport-associated mechanism involving system Xc−, glutathione, and ABCC1. The findings separate this protective response from canonical TLR4 and caspase-11 signaling and provide a useful framework for studying immune-cell preservation during chemotherapy.

• GSK343: EZH2 Inhibitor Workflow

  2026-08-20

  GSK343 is a cell-permeable, SAM-competitive EZH2 inhibitor for testing how PRC2-driven H3K27me3 shapes gene expression and cancer phenotypes. This workflow connects quantitative chromatin assays with breast, prostate, and TERT-focused models while emphasizing controls, solubility, and interpretation limits.

• Novobiocin: Assay Design Beyond MIC Testing

  2026-08-20

  Novobiocin is an aminocoumarin antibiotic whose value extends beyond a single MIC measurement. This guide shows how to connect growth, mechanistic, synergy, host-cell, and translational readouts into a more defensible antimicrobial assay strategy.

• BRD4–RAC1 Co-targeting in Breast Cancer

  2026-08-19

  A 2021 study showed that simultaneous inhibition of BRD4 and RAC1 suppresses breast cancer growth, migration, stem-like behavior, and xenograft tumorigenesis across molecular subtypes. Its key mechanistic contribution was to connect dual pathway inhibition with disruption of the c-MYC–G9a–FTH1 axis and downregulation of HDAC1-associated chromatin regulation.

• Firefly Luciferase mRNA: Assay Workflows

  2026-08-19

  Build sensitive reporter assays, delivery screens, and in vivo imaging workflows with a capped, modified Firefly Luciferase mRNA. Its Cap1 structure, 5-moUTP chemistry, and optimized poly(A) tail support sustained expression while the reference study shows why expression and immune readouts should be analyzed separately by biological sex.

• BRD4770: G9a Inhibition Workflow for Cancer Models

  2026-08-18

  BRD4770 provides a practical route to connect G9a enzymatic inhibition with H3K9 methylation loss, senescence, and cancer-cell growth phenotypes. This workflow emphasizes formulation control, time-resolved epigenetic readouts, and assay choices informed by breast and pancreatic cancer models.

• DHODH Inhibition and TP53 in Nasopharyngeal Cancer

  2026-08-18

  Dong et al. identify pyrimidine biosynthesis and DHODH as metabolically relevant vulnerabilities in nasopharyngeal carcinoma, showing that BAY2402234 suppresses tumor-associated phenotypes through a TP53-dependent mechanism. The study combines multi-dataset bioinformatics with cellular pharmacology, transcriptomics, and TP53 knockdown, providing a framework for evaluating metabolic interventions in tumors with relatively preserved TP53 signaling.

• AL-8810: Prostaglandin F2α Antagonist Workflows

  2026-08-17

  Learn how AL-8810 enables controlled dissection of FP receptor signaling in endometrial, vascular, and smooth muscle models. This practical guide combines assay design, concentration selection, pathway validation, and troubleshooting around PGF2α-driven ERK1/2, MMP-2, and vascular responses.

• NSC 87877: Mapping SHP2 in Neuroinflammation

  2026-08-17

  NSC 87877 is a selective Shp2 inhibitor for dissecting phosphatase-dependent signaling in neuroinflammation. This article distinguishes direct SHP2 blockade from upstream neuromodulation and translates the distinction into practical assay decisions.

• Caffeic Acid Phenethyl Ester (CAPE) NF-κB Workflows

  2026-08-16

  Caffeic Acid Phenethyl Ester (CAPE) provides a practical chemical probe for separating NF-κB-dependent inflammation from broader transcriptional effects. This workflow connects cell-based NF-κB assays with angiogenesis, tumor-invasion, and neuroinflammation models while emphasizing solvent control, pathway-specific validation, and careful interpretation.

8465 records 1/565 page Next 12345 下5页 Last page